Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
FierceBiotech10d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Q2 EPS Estimates for Gilead Sciences Boosted by Analyst
Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...
FiercePharma5d
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
bovnews1d
Gilead Sciences Inc (GILD)’s Stock Surge: What You Need to Know
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...
Hosted on MSN11d
Morgan Stanley Upgrades Gilead Sciences (GILD)
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Business Wire10d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Yahoo Finance6d
Gilead Sciences, US government settle patent case over HIV prevention drugs
(Reuters) - Gilead Sciences and the U.S. government have settled ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health ...